Which act shifted responsibility for drug advertisements to the FTC?

The Kefauver-Harris Amendment is the correct answer because it significantly revised the Federal Food, Drug, and Cosmetic Act, particularly in the area of drug advertising and regulation. Enacted in response to concerns over the safety and efficacy of medications following the thalidomide tragedy in the early 1960s, the amendment established a framework that required drug manufacturers to provide substantial evidence of effective use before their products could gain approval from the FDA.

One key aspect of the Kefauver-Harris Amendment was the shift in the oversight of prescription drug advertisements from the Food and Drug Administration (FDA) to the Federal Trade Commission (FTC). This transition was aimed at ensuring that drug advertisements were not only truthful but also not misleading, allowing the FTC to implement standards regarding advertising and promoting prescription drugs, rather than solely focusing on the clinical safety and efficacy monitored by the FDA.

This change marked a pivotal shift in regulatory authority, creating a clearer distinction between the roles of these two agencies in overseeing various aspects of drug regulation, thus enhancing consumer protection in pharmaceutical advertising. The other acts mentioned do not directly pertain to the regulation of drug advertising in the same manner as the Kefauver-Harris Amendment does.